John Tu, MD
Dermatology · Rochester, NYNPI 1508897083
Payments from drug & device makers
Across 566 payments — averaging $9502.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2.7M
- E.r. Squibb & Sons, L.L.C.$512K
- Biofrontera Bioscience GmbH$458K
- UCB SA$365K
- Amgen$276K
- Aclaris Therapeutics, Inc.$249K
- plus $840K from 26 others
Across 1 payment — averaging $293.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biofrontera Inc.$293
What the payments were for
- Consulting fees$3,05043%
- Travel & lodging$3895%
- Food & beverage$3,64351%
- Gifts$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 177 | $2,677,836 |
| E.r. Squibb & Sons, L.L.C. | 10 | $512,326 |
| Biofrontera Bioscience GmbH | 24 | $457,592 |
| UCB SA | 20 | $364,726 |
| Amgen | 10 | $276,436 |
| Aclaris Therapeutics, Inc. | 29 | $249,435 |
| Novartis | 19 | $211,550 |
| Biofrontera Inc. | 20 | $160,200 |
| Sanofi US Services Inc. | 31 | $128,644 |
| Incyte Corporation | 65 | $122,685 |
| Bausch Health US, LLC | 23 | $78,101 |
| Pfizer(2 entities) | 24 | $41,412 |
| Perrigo Company PLC | 1 | $33,650 |
| UCB Biosciences Inc. | 2 | $30,731 |
| Sun Pharmaceutical Industries Inc. | 45 | $17,124 |
| Arcutis Biotherapeutics, Inc. | 2 | $7,636 |
| LEO Pharma AS | 2 | $3,486 |
| Dr.reddy's Laboratories,inc. | 3 | $2,659 |
| Almirall LLC | 1 | $800 |
| Regeneron Healthcare Solutions, Inc. | 6 | $441 |
| UCB, Inc. | 9 | $224 |
| Johnson & Johnson | 14 | $196 |
| Janssen Scientific Affairs, LLC | 1 | $112 |
| Lilly USA, LLC | 6 | $104 |
| Bristol Myers Squibb | 5 | $87 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $57 |
| LEO Pharma Inc. | 2 | $53 |
| Prugen, Inc. Pharmaceuticals | 6 | $45 |
| Sandoz | 2 | $36 |
| DUSA Pharmaceuticals, Inc. | 1 | $19 |
| Sanofi | 1 | $14 |
| Mayne Pharma Commercial LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMELUZ$3,219
- BF-RhodoLED$2,358
- XEPI$2,358
- BF-RhodoLED XL$861
- Klisyri$800
- DUPIXENT$372
- COSENTYX$247
- Skyrizi$125
- Humira$123
- Tremfya$112
How this compares
$5,378,427 in reported general payments places this provider in the 95th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 23 | $215,403 |
| Humira(Cf) PenAdalimumab | 14 | $177,507 |
| OtezlaApremilast | 13 | $64,341 |
| Fluorouracil | 103 | $6,982 |
| Mometasone Furoate | 203 | $4,536 |
| Betamethasone Dipropionate | 73 | $3,491 |
| Tacrolimus | 15 | $2,504 |
| Clobetasol Propionate | 42 | $2,018 |
| Ammonium Lactate | 79 | $2,008 |
| Doxycycline Hyclate | 58 | $1,718 |
| Metronidazole | 23 | $1,060 |
| Minoxidil | 89 | $963 |
| Fluocinonide | 15 | $859 |
| Ketoconazole | 53 | $820 |
| Clindamycin Phosphate | 23 | $816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $276,436 | $64,34113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,151 dermatology providers in New York.
Other dermatology in Rochester
- Lisa BeckRochester$2.3M
- Anna DebenedettoRochester$749K
- Mary Gail MercurioRochester$655K
- Emma GuttmanNew York$35.3M
- Saakshi KhattriNew York$15.4M
- James KruegerNew York$6.3M
- Michael CameronNew York$5.8M
- Mark LebwohlNew York$5.8M
- Andrew AlexisNew York$5.7M
- Jeffrey WeinbergKew Gardens$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.